The main department of described VC is located in the Boston. The venture was found in North America in United States.
Besides them, we counted 1 critical employee of this fund in our database.
The real fund results show that this VC is 9 percentage points less often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2014. This Chiesi Ventures works on 18 percentage points less the average amount of lead investments comparing to the other organizations.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Chiesi Ventures, startups are often financed by Caixa Capital Risc, Ysios Capital, Healthequity. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Sanderling Ventures, Roche Venture Fund. In the next rounds fund is usually obtained by Ysios Capital, Sanderling Ventures, Sambrinvest.
Among the various public portfolio startups of the fund, we may underline Minoryx Therapeutics, VelosBio, 4D Molecular Therapeutics The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics.
Funds with similar focus
|3W Partners||Missouri, Saint Louis, United States|
|Altos Venture||Allschwil, Basel-Landschaft, Switzerland|
|Blue Ocean Capital Group||China, Guangdong, Shenzhen|
|Blue Wave Innovation Capital||County Dublin, Dublin, Ireland|
|Chartwell Investments||New York, New York, United States|
|China Asset Management||Beijing, Beijing, China|
|Davidson consulting||Boulogne-Billancourt, France, Ile-de-France|
|Emergent Game Technologies||Calabasas, California, United States|
|Invitalia||Italy, Lazio, Roma|
|IPF Partners||Luxembourg, Luxembourg|
|JSW Ventures||India, Maharashtra, Mumbai|
|Kite Ventures||Moscow, Moscow, Russia|
|Pepper Media Holding||Berlin, Berlin, Germany|
|Sparbanksstiftelse Norrlands Riskkapitalstiftelse||-|
|Suzhou Decheng Hongxing Touzi||China, Jiangsu, Suzhou|
|Taiheng Touzi||China, Hangzhou, Zhejiang|
|Verve Capital||Florida, Miami, United States|
|Zhejiang Wanghe Touzi Guanli Gufen Youxian Gongsi||China, Hangzhou, Zhejiang|
|$35M||23 Jun 2021||San Francisco, California, United States|
|$80M||22 Mar 2021||Cambridge, Massachusetts, United States|
|$95M||09 Dec 2020||San Diego, California, United States|
4D Molecular Therapeutics
|$75M||16 Jun 2020||California, United States|
|$33M||07 Aug 2019||San Francisco, California, United States|
|$120M||07 Nov 2018||San Diego, California, United States|
|$54M||17 Oct 2018||California, United States|
|$58M||01 Oct 2018||-|
|$25M||26 Sep 2018||Barcelona, Catalonia, Spain|
– Aura Biosciences closed an oversubscribed $80m financing.
– The financing was led by Matrix Capital Management and Surveyor Capital (a Citadel company) with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital.
– Existing investors Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners also participated in the round.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.